References
Franz PM, Mattiuz EL, Rubin A, et al. Disposition of [14C]-zatosetron, a selective and potent serotonin receptor (5HT3) antagonist, in healthy men after oral administration. FASEB J 1992 Feb 26; 6: A1570
Chappell AS, Bay JM, Botzum GD, et al. Zatosetron, a 5-HT(3) receptor antagonist in a multicenter trial for acute migraine. Neuropharmacology 1994 Mar-Apr; 33: 509–13
Smith WT, Londborg PD, Blomgren SL, et al. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol 1999 Apr; 19: 125–31
Cohen ML, Bloomquist W, Schmid CR, et al. Zatosetron, a selective 5-HT3 receptor antagonist: pharmacological activities of human and animal metabolites. Drug Dev Res 1993 Jul; 29: 209–15
Williams PD, Calligaro DO, Colbert WE, et al. General pharmacology of a new potent 5-hydroxytryptamine antagonist. Arzneimittel Forschung 1991 Mar; 41: 189–95
Schwartz SM, Goldberg MJ, Gidda JS, et al. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men. J Clin Pharmacol 1994 Mar; 34: 250–4
Rights and permissions
About this article
Cite this article
Zatosetron. Drugs R&D 2, 253–255 (1999). https://doi.org/10.2165/00126839-199902040-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902040-00009